2022-11-10T15:41:45-06:00 2021-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2021-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 LINDA JENSEN EVP & CFO 5714831300 2022-11-10 1 LINDA JENSEN 999009999 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2022-11-09 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z ASCO CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 148501210 0 X WWW.ASCO.ORG X 1965 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGHRESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. 19 19 519 5185 14311943 7677032 6446971 7826511 121740555 95200297 -4680218 -6626473 14866774 11188293 138374082 107588628 7819588 4188723 0 0 58815087 59715405 0 0 0 68101126 55874509 134735801 119778637 3638281 -12190009 279249289 283820689 119295053 114592790 159954236 169227899 X SEE SCHEDULE O 0 0 34763068 0 22991694 QUALITY OF CARE: SEE SCHEDULE O 26185693 0 53330502 SCIENTIFIC AND MEDICAL EDUCATION: SEE SCHEDULE O 9491583 161000 14349944 SCIENTIFIC PUBLICATIONS: SEE SCHEDULE O 25044237 4027723 4474437 1. MEMBERS SERVICES: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 45,000 MEMBERS, IN COLLABORATION WITH ITS AFFILIATE, ASCO ASSOCIATION, D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY (ASSOCIATION). ASCO AND THE ASSOCIATION HAVE RECIPROCAL MEMBERSHIP, MEANING THAT EACH MEMBER IS A MEMBER OF BOTH ASCO AND THE ASSOCIATION. ASCO'S MEMBERS VOLUNTEER TO PROVIDE EXPERTISE FOR EDUCATION, PRACTICE GUIDELINES, POLICY, AND OTHER ONCOLOGY LEADERSHIP ACTIVITIES.2. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH-RELATED ACTIVITIES INCLUDE:- ORIGINAL RESEARCH: ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. ITS MAJOR CLINICAL TRIAL, TAPUR, IS TESTING THE SAFETY AND EFFICACY OF FDA- APPROVED, TARGETED ANTI-CANCER THERAPIES IN OTHER CANCER TYPES FOR PATIENTS WITH AN INDICATIVE GENOMIC ALTERATION. IN 2020, ASCO LAUNCHED A REGISTRY TO COLLECT AND ANALYZE THE IMPACT OF COVID-19 ON CANCER PATIENT OUTCOMES. - SCIENTIFIC/RESEARCH COLLABORATIONS: ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE- BASED PATIENT CARE. THIS INCLUDES AN ASCO-FDA COLLABORATION TO JOINTLY HOST PUBLIC WORKSHOPS ON EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES.- RESEARCH GRANTS AND AWARDS: ASCO MAKES GRANTS TO ITS 501(C)(3) AFFILIATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CONQUER CANCER) TO FUND COMPETITIVELY AWARDED RESEARCH GRANTS AND AWARDS. MOST OF THESE GRANTS SUPPORT THE INDEPENDENT RESEARCH INITIATIVES OF CLINICAL INVESTIGATORS.3. CANCER POLICY: ASCO'S POLICY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY AND EQUITABLE CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY DEVELOPS POSITIONS ADDRESSING ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OFONCOLOGY AND PATIENT CARE. ASCO'S POLICY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINELY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE.4. PATIENT INFORMATION AND OTHER: ASCO PROVIDES IMPORTANT INFORMATION TO THE PUBLIC FREE OF CHARGE THROUGH ITS AWARD-WINNING PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), THROUGH A MOBILE APPLICATION, AND OTHER PATIENT EDUCATION MATERIALS. CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. CANCER.NET PROVIDES ONCOLOGIST- APPROVED INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. THE SITE OFFERS COMPREHENSIVE GUIDES TO MORE THAN 120 TYPES OF CANCER AND CANCER-RELATED SYNDROMES, INCLUDING DISEASE-SPECIFIC TREATMENT AND SIDE EFFECTS INFORMATION. EXTENSIVE INFORMATION CAN BE FOUND ON NAVIGATING CANCER CARE, COPING WITH CANCER, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, SURVIVORSHIP, AND RESEARCH AND ADVOCACY; SELECT CONTENT IS AVAILABLE IN SPANISH, CHINESE, PORTUGUESE, ROMANIAN, ARABIC, GREEK, AND ARMENIAN. CANCER.NET ALSO FEATURES VIDEOS, PODCASTS, AND AN AWARD-WINNING BLOG. 25044237 4027723 4474437 95484581 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 1 361 0 1 519 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 19 19 1 0 1 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY VA X LINDA JENSEN EVP & CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 HOWARD A BURRIS III MD CHAIR/PAST PRESIDENT 1.00 3.00 X X 0 0 0 LORI J PIERCE MD CHAIR/PRESIDENT 1.00 1.00 X X 0 0 0 MONICA M BERTAGNOLLI MD PAST PRESIDENT (PARTIAL YR) 1.00 1.00 X X 0 0 0 EVERETT E VOKES MD PRESIDENT 1.00 1.00 X X 0 0 0 ERIC P WINER MD PRESIDENT- ELECT 1.00 X X 0 0 0 ELIZABETH A MITTENDORF MD TREASURER- ELECT 1.00 1.00 X X 0 0 0 LAURIE E GASPAR MD MBA TREASURER 1.00 1.00 X X 0 0 0 ETHAN M BASCH MD BOARD MEMBER 1.00 X 0 0 0 A WILLIAM BLACKSTOCK MD BOARD MEMBER 1.00 1.00 X 0 0 0 LISA A CAREY MD BOARD MEMBER 1.00 X 0 0 0 ENRIQUE SOTO PEREZ DE CELIS MD PHD BOARD MEMBER 1.00 X 0 0 0 LEE M ELLIS MD BOARD MEMBER 1.00 1.00 X 0 0 0 TARA O HENDERSON MD MPH BOARD MEMBER 1.00 X 0 0 0 RESHMA JAGSI MD BOARD MEMBER (PARTIAL YR) 1.00 1.00 X 0 0 0 MICHAEL P KOSTY MD BOARD MEMBER (PARTIAL YR) 1.00 1.00 X 0 0 0 TONY S K MOK BMSC MD BOARD MEMBER 1.00 1.00 X 0 0 0 ELIZABETH R PLIMACK MD MS BOARD MEMBER 1.00 X 0 0 0 ERIC J SMALL MD BOARD MEMBER (PARTIAL YR) 1.00 1.00 X 0 0 0 MICHAEL A THOMPSON MD PHD BOARD MEMBER 1.00 X 0 0 0 TRACEY F WEISBERG MD BOARD MEMBER 1.00 X 0 0 0 MARIANA CHAVEZ MACGREGOR MD BOARD MEMBER 1.00 X 0 0 0 TAOFEEK OWONIKOKO MD PHD BOARD MEMBER 1.00 X 0 0 0 GLADYS RODRIGUEZ MD BOARD MEMBER 1.00 X 0 0 0 CLIFFORD HUDIS MD CHIEF EXECUTIVE OFFICER 30.00 7.50 X 888725 0 21750 DINA MICHELS ESQ SECRETARY, EVP & COO 33.50 4.00 X 595328 0 40279 LINDA JENSEN CPA EVP AND CFO 30.00 7.50 X 408048 0 42559 SEAN KHOZIN MD EVP & CEO OF CANCERLINQ 37.50 X 409799 0 28835 JULIE R GRALOW MD EVP & CHIEF MEDICAL OFFICER 37.50 X 483927 0 37233 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICE 37.50 X 421998 0 47344 JAMIE VON ROENN MD VP, EDU., SCIENCE & PROF. 37.50 X 410114 0 30545 NANCY DALY MS MPH EVP & CEO CONQUER CANCER F 1.00 36.50 X 415557 0 46187 ANGELA COCHRAN VP, PUBLISHING 37.50 X 248480 0 35036 KRISTIN LUDWIG VP, MARKETING & COMMUNICAT 37.50 X 311775 0 21750 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 37.50 X 261391 0 27979 BARTON LAWYER VICE PRESIDENT - IT 37.50 X 249998 0 46718 STEPHEN GRUBBS MD VICE PRESIDENT, CARE DELIV 37.50 X 400196 0 39421 ROBERT MILLER MD MEDICAL DIRECTOR, CANCERLI 37.50 X 361599 0 46863 CARMEN JACKSON CHIEF OF OPERATIONS, CLQ 37.50 X 305276 0 47158 ANIL NAIR CHIEF TECHNOLOGY OFFICER, 37.50 X 299475 0 37248 DEBORAH KAMIN RN PHD VP POLICY & ADVOCAY 37.50 X 308317 0 43437 6780003 0 640342 216 0 1 0 SPARGO INC 11208 WAPLES MILL ROAD 112 FAIRFAX VA 22030 EVENT MANAGEMENT 5080732 TEMPUS LABS LLC 600 WEST CHICAGO AVE CHICAGO IL 60654 DATA CURATION 4547807 CONCERTO HEALTH AI SOLUTIONS LLC 501 BOYLSTON ST BOSTON MA 02116 DATA TECHNOLOGY 3714413 PUBLICIS SAPIENT 1515 NORTH COURTHOUSE ROAD 4TH FLO ARLINGTON VA 22201 DIG. TRANSFORMATION 1967426 M BOOTH HEALTH LLC 111 5TH AVE NEW YORK NY 10003 COMMUNICATIONS & CONSULTING 1071805 78 7826511 7826511 EDUCATIONAL MTGS & FEE 900099 53330502 46286080 7044422 QUALITY OF CARE 900099 22991694 22991694 SCIENTIFIC PUBLICATION 511190 14349944 7082423 7267521 RESEARCH 900099 4322682 4322682 OTHER 900099 151755 151755 53720 53720 95200297 4026599 4026599 11188293 11188293 30259510 40912582 -10653072 -10653072 -10653072 107588628 80888354 14311943 4561820 X 4165660 4165660 23063 23063 5559490 4000579 1558911 42467496 30683434 11784062 3173377 2169504 1003873 4920266 3363777 1556489 3594776 2457596 1137180 819829 327201 492628 194067 194067 66140 66140 18649631 16410543 2239088 5027126 5003918 23208 2096676 1513917 582759 9834857 9430467 404390 1398004 1331336 66668 349952 282469 67483 2168888 2059898 108990 1289357 768199 521158 3857950 2298567 1559383 647450 234023 413427 UBI TAX- FEDERAL AND ST 3362389 3362389 CLINICAL SITE PAYMENTS 2990900 2990900 PUBLICATIONS & PRODUCTI 2373249 2368874 4375 DUES & SUBSCRIPTIONS 563864 229763 334101 184180 8504 175676 119778637 95484581 24294056 0 103 19356599 25343458 26710378 13783464 5600000 4696784 5424995 5397152 82065544 35134679 48956971 46930865 173200346 181953164 0 5715699 279249289 283820689 10180370 11649507 38354168 46913692 38400000 0 15345000 49295410 17015515 6734181 119295053 114592790 X 159229656 168691045 724580 536854 159954236 169227899 279249289 283820689 X -12190009 20071318 66140 1326214 X X 0 1 X 1 0 X 9978694 8575801 7525300 6446971 7826511 40353277 93297144 136574903 123116955 98737324 80888354 532614680 103275838 145150704 130642255 105184295 88714865 572967957 75000 75000 0 75000 75000 572892957 5969247 7763043 8610595 18248056 15214892 55805833 5969247 7763043 8610595 18248056 15214892 55805833 2871782 4855029 7776132 8302393 7677032 31482368 248859 255345 251085 755289 112365726 158024121 147280067 131734744 111606789 661011447 0.86670 0.88530 0.08440 0.07120 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 95484581 95484581 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 198306 43604 0 0 241910 250000 250000 250000 250000 1000000 1500000 1947 263 0 0 2210 7342677 7342677 46941779 15774810 31166969 780214 774926 5288 5159032 3814409 1344623 21841842 14770534 7071308 46930865 DEFERRED COMPENSATION LIABILITY 3244563 OPERATING LEASE OBLIGATION 3167141 ACCRUED TAXES PAYABLE 322477 6734181 X PART X, LINE 2: IN PART: THE SOCIETY IS A NON-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE "IRC"). IT HAS BEEN GRANTED PUBLIC CHARITY STATUS BY THE INTERNAL REVENUE SERVICE (THE "IRS") AND HAS BEEN CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. CANCERLINQ, AND ASCO LEASING LLC ARE DISREGARDED ENTITIES FOR INCOME TAX PURPOSES AND INCLUDED WITH THE SOCIETY'S RETURN. THE SOCIETY RECEIVES TAXABLE REVENUE RELATED TO ADVERTISING. FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020, ASCO RECORDED APPROXIMATELY $3,350,336 AND $3,495,000, RESPECTIVELY, IN NET FEDERAL AND STATE INCOME TAXES. AS OF DECEMBER 31, 2021 AND 2020, THE ORGANIZATION HAS OUTSTANDING DEFERRED TAX ASSETS RELATED TO THE EXCESS OF A TAX "DEDUCTION LIMITATION ON CHARITABLE CONTRIBUTIONS OF APPROXIMATELY $4,428,000 AND $4,044,000, RESPECTIVELY, WHICH MAY BE CARRIED FORWARD FOR A MAXIMUM OF FIVE YEARS THROUGH 2024. MANAGEMENT ASSESSED THE REALIZATION OF ITS DEFERRED TAX ASSETS AND RECORDED A FULL VALUATION ALLOWANCE AS MANAGEMENT BELIEVES THAT IT IS MORE LIKELY THAN NOT THAT SOME OR ALL OF ITS DEFERRED TAX ASSETS WILL NOT BE REALIZED BEFORE THEIR EXPIRATION. THE ORGANIZATION ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2018. 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 9833 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES, GRANTMAKING OUTREACH & EDUCATION 70913 NORTH AMERICA 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 9000 SOUTH AMERICA 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 5500 SOUTH ASIA 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 5000 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 3000 0 0 0 0 0 0 103246 0 103246 CANCER COMMUNITY SUPPORT EUROPE (INCLUDING ICELAND & GREENLAND) 1 23063 WIRE 0 0 0 0 0 1 PART I, LINE 2: ASCO PROVIDED HONORARIA, VIRTUAL BOOTH FEES AND EXPENSE REIMBURSEMENTS TO MEETING SPEAKERS AND PRESENTERS. HONORARIA AND EXPENSE REIMBURSEMENTS WERE PAID DIRECTLY TO THE PRESENTERS. VIRTUAL BOOTH FEES WERE PAID TO THE VENDOR. PART I, LINE 3: THE ACCRUAL METHOD WAS USED TO ACCOUNT FOR EXPENDITURES IN RELATION TO BOTH FOREIGN PROGRAM SERVICES & GRANTMAKING ACTIVITIES. PART III ACCOUNTING METHOD: 1 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561693 501(C)(6) 40000 0 MISSION ENDOWMENT FOR MEMBERS SERVICES FOR INTERNATIONAL MEMBERSHIP BANNER MEDICAL GROUP 1 N CENTRAL AVE SUITE 160 PHOENIX AZ 85004 900532830 501(C)(3) 60000 0 CONTRIBUTION BOARD OF REGENTS OF THE UNIVERSITY OF THE UNIVERSITY OF MICHIGAN 3003 S STATE ST SUITE 8000 ANN ARBOR MI 48109 386006309 501(C)(3) 119167 0 CONTRIBUTION BRIGHAM & WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON MA 02116 042312909 501(C)(3) 30000 0 CONTRIBUTION CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 3566050 0 CONTRIBUTION DANA FARBER CANCER INSTITUTE 10 BROOKLINE PLACE W BROOKLINE MA 02445 042263040 501(C)(3) 41430 0 CONTRIBUTION DUKE UNIVERSITY 2200 W MAIN ST SUITE 820 DURHAM NC 27705 560532129 501(C)(3) 25000 0 CONTRIBUTION FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SOUTH WASHINGTON DC 20036 521983273 501(C)(3) 25000 0 CONTRIBUTION HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW SUITE 310 WASHINGTON DC 20036 521485477 501(C)(3) 10000 0 CONTRIBUTION NATIONAL COALITION FOR CANCER SURVIVORSHIP 8455 COLESVILLE RD SUITE 930 SILVER SPRINGS MD 20910 850357897 501(C)(3) 10000 0 CONTRIBUTION SARAH CANON RESEARCH INSTITUTE OF HCA HEALTHCARE 3322 WEST END AVE SUITE 900 NASHVILLE TN 37203 201557751 N/A 60000 0 CONTRIBUTION UNIVERSITY OF CHICAGO 5801 ELLIS AVE CHICAGO IL 60637 362177139 501(C)(3) 163600 0 CONTRIBUTION 10 2 PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. GRANTS MADE TO NON-501(C)(3) ORGANIZATIONS ARE MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X 0 0 0 0 0 0 0 1 0 CLIFFORD HUDIS MD CHIEF EXECUTIVE OFFICER 886337 0 1200 0 1188 0 21750 0 0 0 910475 0 0 0 DINA MICHELS ESQ SECRETARY, EVP & COO 591777 0 1700 0 1851 0 21750 0 18529 0 635607 0 0 0 JULIE R GRALOW MD EVP & CHIEF MEDICAL OFFICER 481922 0 1000 0 1005 0 21750 0 15483 0 521160 0 0 0 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICE 420584 0 1000 0 414 0 21750 0 25594 0 469342 0 0 0 NANCY DALY MS MPH EVP & CEO CONQUER CANCER F 413369 0 1000 0 1188 0 21750 0 24437 0 461744 0 0 0 LINDA JENSEN CPA EVP AND CFO 404497 0 1200 0 2351 0 21750 0 20809 0 450607 0 0 0 JAMIE VON ROENN MD VP, EDU., SCIENCE & PROF. 399211 0 1000 0 9903 0 21750 0 8795 0 440659 0 0 0 STEPHEN GRUBBS MD VICE PRESIDENT, CARE DELIV 396910 0 1000 0 2286 0 21750 0 17671 0 439617 0 0 0 SEAN KHOZIN MD EVP & CEO OF CANCERLINQ 408571 0 1000 0 228 0 21750 0 7085 0 438634 0 0 0 ROBERT MILLER MD MEDICAL DIRECTOR, CANCERLI 357672 0 2000 0 1927 0 21750 0 25113 0 408462 0 0 0 CARMEN JACKSON CHIEF OF OPERATIONS, CLQ 283096 0 22000 0 180 0 21564 0 25594 0 352434 0 0 0 DEBORAH KAMIN RN PHD VP POLICY & ADVOCAY 303609 0 1000 0 3708 0 21750 0 21687 0 351754 0 0 0 ANIL NAIR CHIEF TECHNOLOGY OFFICER, 276701 0 22000 0 774 0 20962 0 16286 0 336723 0 0 0 KRISTIN LUDWIG VP, MARKETING & COMMUNICAT 310001 0 1000 0 774 0 21750 0 0 0 333525 0 0 0 BARTON LAWYER VICE PRESIDENT - IT 248584 0 1000 0 414 0 19125 0 27593 0 296716 0 0 0 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 259211 0 2000 0 180 0 19500 0 8479 0 289370 0 0 0 ANGELA COCHRAN VP, PUBLISHING 247210 0 1000 0 270 0 18750 0 16286 0 283516 0 0 0 PART I, LINE 7 THE ORGANIZATION HAS A DISCRETIONARY BONUS PLAN UNDER WHICH SELECTED EMPLOYEES, INCLUDING OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES ARE COMPENSATED BASED ON PERFORMANCE AND THE ACHIEVEMENT OF ORGANIZATIONAL GOALS. BONUSES FOR KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES ARE APPROVED BY THE CHIEF EXECUTIVE OFFICER WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. IN ADDITION, THE ORGANIZATION AWARDS MODEST AMOUNTS TO EMPLOYEES ON ACHIEVING CERTAIN NUMBER OF YEARS OF EMPLOYMENT. FROM TIME TO TIME, THE ORGANIZATION MAY MAKE STANDARD PAYMENTS TO ITS EMPLOYEES IN GOOD STANDING WITH MINIMUM TIME OF EMPLOYMENT TO RECOGNIZE EFFORT AND COMMITMENT TO THE ORGANIZATION'S GOALS IN THAT YEAR. FORM 990, PART III, LINE 1 ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - LIFELONG LEARNING FOR ONCOLOGY PROFESSIONALS, - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. FORM 990, PART III, LINE 4A: QUALITY OF CARE: ASCO, THROUGH COLLECTION OF ONCOLOGY PRACTICE CARE DELIVERY METRICS, DEVELOPS INSIGHTS TO IMPROVE THE QUALITY AND EQUITY OF ONCOLOGY CARE DELIVERY. ASCO ALSO PRODUCES EVIDENCE-BASED GUIDELINES, QUALITY MEASURES AND DEVELOPS STANDARDS FOR QUALITY ONCOLOGY CARE, AND PROVIDES TRAINING IN QUALITY CARE IMPROVEMENT. CANCERLINQ'S BIG-DATA PLATFORM DELIVERS VALUABLE INSIGHTS AND TOOLS TO PARTICIPATING PRACTICES AND DE-IDENTIFIED DATA FOR CANCER TREATMENT RESEARCH. THE CANCERLINQ DATABASE, WHICH INCLUDES INFORMATION FROM MILLIONS OF CANCER PATIENT CARE RECORDS, REFLECTS CANCER CARE IN ALL ITS REAL-WORLD VARIABILITY, ALLOWING CLINICIANS TO LEARN FROM THE EXPERIENCE OF EVERY PATIENT. QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN PRACTICES THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. FORM 990, PART III, LINE 4B: SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS MEETINGS ON THE LATEST CANCER RESEARCH AND EDUCATIONAL SESSIONS HIGHLIGHTING ADVANCES IN RESEARCH AND ONCOLOGY CARE. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE, ASSISTING THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS ONGOING RESEARCH AND THE MODERN- DAY PRACTICE OF ONCOLOGY FOR THE COMMUNITY OF MULTIDISCIPLINARY ONCOLOGY CARE PROVIDERS. ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL CLINICAL ONCOLOGY MEETING. ASCO ALSO SPONSORS OR CO-SPONSORS THEMATIC MEETINGS (FOCUSING ON SUBSPECIALTY AREAS), WHICH PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. HIGHLIGHTS OF THE 2021 VIRTUAL ANNUAL MEETING INCLUDE OVER 5,000 SCIENTIFIC ABSTRACTS FOR NEARLY 33,000 ATTENDEES. THE GASTROINTESTINAL CANCERS AND THE GENITOURINARY CANCERS SYMPOSIA COVERED 751 AND 580 ABSTRACTS, RESPECTIVELY, FOR 4,100 AND 5,150 ATTENDEES. CONTENT IS MAINTAINED DIGITALLY AND MADE ACCESSIBLE. DUE TO THE COVID-19 PANDEMIC, ASCO'S MEETINGS WERE PRESENTED VIRTUALLY THROUGH JUNE, 2021. THESE MEETINGS ARE NOW PRESENTED IN BOTH A VIRTUAL AND IN-PERSON (HYBRID) FORMAT. THE HYBRID FORMAT HAS ENABLED PARTICIPATION FROM A LARGER AND MORE DIVERSE DOMESTIC AND INTERNATIONAL AUDIENCE. ASCO'S SCIENTIFIC AND EDUCATION PROGRAMS ALSO INCLUDE DIGITAL EDUCATION PROGRAMS, PROFESSIONAL DEVELOPMENT ACTIVITIES, AND LICENSING PROGRAMS THAT ALLOW ASCO TO BROADLY DELIVER ITS MATERIALS AND EDUCATION FOR THE ENTIRE SPECTRUM OF PROFESSIONALS WORKING IN ONCOLOGY CARE. IN 2021, ASCO HELD THE STATUS OF JOINT ACCREDITATION FROM THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION, ALLOWING ASCO TO PROVIDE CONTINUING EDUCATION CREDIT FOR PHYSICIANS, NURSES AND PHARMACISTS. FORM 990, PART III, LINE 4C: SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED JOURNAL PUBLISHING SCIENTIFIC MANUSCRIPTS AND ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JCO IS MAILED THREE A TIMES A MONTH TO OVER 17,000 ASCO MEMBERS. OVER 3,000 GLOBAL INSTITUTIONS SUBSCRIBE TO THE PUBLICATION, PRINT AND ONLINE. - JCO ONCOLOGY PRACTICE (JCO OP) PUBLISHES ORIGINAL RESEARCH AND INSIGHTS TO KEEP ONCOLOGY PRACTICES CURRENT ON CHANGES AND CHALLENGES INHERENT IN DELIVERING EQUITABLE, HIGH-QUALITY ONCOLOGY CARE WITH AN EVOLVING VALUE-BASED LENS. ALL CONTENT DEALING WITH UNDERSTANDING THE PROVISION OF CARE - THE MECHANICS OF PRACTICE, CARE DELIVERY, QUALITY IMPROVEMENT, VALUE, AND EQUITY - IS THE PURVIEW OF JCO OP. JCO OP ALSO ADDRESSES AN EXPRESSED NEED BY PRACTICING PHYSICIANS TO HAVE COMPRESSED, EXPERT OPINION ADDRESSING COMMON CLINICAL PROBLEMS WITH PERSPECTIVES BY DISEASE EXPERTS. JCO OP MAILS MONTHLY TO APPROXIMATELY 24,000 ASCO MEMBERS AS WELL AS AFFILIATED MEDICAL PROFESSIONALS. - JCO GLOBAL ONCOLOGY (JCO GO) IS AN ONLINE-ONLY, OPEN ACCESS JOURNAL FOCUSING ON CANCER CARE, RESEARCH, AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. - JCO CLINICAL CANCER INFORMATICS (JCO CCI) IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL THAT PUBLISHES CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION, AND IMAGES. - JCO PRECISION ONCOLOGY (JCO PO) IS AN ONLINE-ONLY JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS, AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINES GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. ASCO DAILY NEWS IS THE OFFICIAL CONFERENCE REPORT OF ASCO, WHICH PROVIDES SCIENTIFIC AND EDUCATIONAL SUMMARIES FROM ONCOLOGY CONFERENCES. IT IS MAILED TO OVER 10,000 ASCO MEETING ATTENDEES FOR THE ASCO ANNUAL MEETING AND THEMATIC MEETINGS. THE ONLINE VERSION PUBLISHES CONTENT YEAR-ROUND. ASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY. FORM 990, PART VI, SECTION A, LINE 1A AS OF DECEMBER 31, 2021, THE BOARD OF DIRECTORS OF ASCO INCLUDED 19 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDED ONE EX-OFFICIO DIRECTOR WITHOUT THE RIGHT TO VOTE, WHO WAS THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, THE TREASURER-ELECT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED MEETING OF THE BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2 DR. LORI J. PIERCE, FASTRO, FASCO, SERVED AS PRESIDENT AND CHAIR OF ASCO AND AS A MEMBER OF THE ASCO BOARD OF DIRECTORS DURING 2021. SHE ALSO SERVES AS A PROFESSOR OF THE DEPARTMENT OF RADIATION ONCOLOGY AT THE UNIVERSITY OF MICHIGAN, AND AS VICE PROVOST FOR ACADEMIC AND FACULTY AFFAIRS. DR. RESHMA JAGSI, FASTRO, FASCO, SERVED AS A MEMBER OF THE ASCO BOARD OF DIRECTORS DURING 2021. SHE ALSO SERVES AS DEPUTY CHAIR OF RADIATION ONCOLOGY AT THE UNIVERSITY OF MICHIGAN. DR. CLIFFORD HUDIS, LINDA JENSEN, AND MELISSA TAI WERE ALL EMPLOYED BY THE ASSOCIATION'S AFFILIATE, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (THE SOCIETY), A SECTION 501(C)(3) PUBLIC CHARITY. DR. HUDIS IS THE CHIEF EXECUTIVE OFFICER OF THE SOCIETY AND MS. JENSEN IS THE CHIEF FINANCIAL OFFICER AND EXECUTIVE VICE PRESIDENT OF THE SOCIETY. DR. MONICA BERTAGNOLLI, DR. HOWARD BURRIS, III, DR. ERIC SMALL, DR. A. WILLIAM BLACKSTOCK, DR. LEE ELLIS, DR. LAURIE GASPAR, DR. RESHMA JAGSI, DR. MICHAEL KOSTY, DR. ELIZABETH MITTENDORF, DR. TONY MOK, DR. LORI PIERCE, DR. EVERETT VOKES, DR. TRACEY WEISBERG, AND DR. ERIC WINER ALL SERVED AS VOTING MEMBERS OF THE SOCIETY'S BOARD OF DIRECTORS DURING THE TAX YEAR. IN ADDITION, DURING THE TAX YEAR, DR. BERTAGNOLLI SERVED AS PAST PRESIDENT OF THE SOCIETY, DR. BURRIS SERVED AS CHAIR OF THE BOARD AND PAST PRESIDENT OF THE SOCIETY, DR. PIERCE SERVED AS PRESIDENT AND CHAIR OF THE BOARD OF THE SOCIETY, DR. VOKES SERVED AS PRESIDENT-ELECT AND PRESIDENT OF THE SOCIETY, DR. WINER SERVED AS PRESIDENT-ELECT OF THE SOCIETY, DR. GASPAR SERVED AS TREASURER OF THE SOCIETY, AND DR. MITTENDORF SERVED AS TREASURER-ELECT OF THE SOCIETY. FORM 990, PART VI, SECTION A, LINE 4 THE ASCO MEMBERSHIP APPROVED AMENDMENTS TO ASCO'S CERTIFICATE OF INCORPORATION AND BYLAWS THAT BECAME EFFECTIVE IN 2021. THE CERTIFICATE OF INCORPORATION WAS AMENDED TO PERMIT THE VOTING MEMBERS TO TAKE ACTION BY WRITTEN CONSENT IF (1) NO FEWER THAN 100 MEMBERS ELIGIBLE TO VOTE CONSENT TO SUCH ACTION IN WRITING OR ELECTRONICALLY, AND (2) SUCH ACTION IS APPROVED BY THE PROPORTION OF VOTES CAST BY MEMBERS ELIGIBLE TO VOTE AS WOULD BE REQUIRED TO APPROVE SUCH ACTION IF THE VOTES WERE CAST AT A MEETING OF THE MEMBERS. THE SIGNIFICANT AMENDMENTS TO THE BYLAWS INCLUDE THE FOLLOWING: ENHANCED BENEFITS FOR ALL MEMBERS WITH DOCTORAL-LEVEL DEGREES. PREVIOUSLY, THE BYLAWS MADE REFERENCE TO SPECIFIC CLASSES OF MEMBERS, SPECIFYING THAT "FULL MEMBERS" WERE PHYSICIANS ANDSOMEDOCTORAL LEVEL PROVIDERS, AND"OTHER MEMBERS" WERE MEMBER CLASSES AS DEFINED IN THE POLICY ADOPTED BY THE ASCO AND THE ASSOCIATION BOARDS OF DIRECTORS. UNDER THE PREVIOUS BYLAWS AND THE ASCO MEMBERSHIP POLICY, FULL MEMBERS AND SOME OF THE CATEGORIES OF OTHER MEMBERS HAD VOTING RIGHTS AND WERE ELIGIBLE TO SERVE ON THE ASCO BOARD OF DIRECTORS, ON THE ASCO NOMINATING COMMITTEE, OR AS ASCO ELECTED OFFICERS. TOGETHER, THOSE CATEGORIES REPRESENTED APPROXIMATELY 57% OF THE TOTAL ASCO MEMBERSHIP. THE AMENDMENTS REPLACED THE EXISTING CONCEPT OF "FULL MEMBERS AND "OTHER MEMBERS" WITH THE CONCEPT OF "MEMBERS AND "VOTING MEMBERS". UNDER THE AMENDED BYLAWS, "MEMBERS" REFERS TO ALL ASCO MEMBERS. "VOTING MEMBERS" REFERS TO THOSE MEMBERS WHO HAVE VOTING RIGHTS, AND ARE ELIGIBLE TO SERVE ON THE ASCO BOARD OF DIRECTORS, ON THE ASCO NOMINATING COMMITTEE, OR AS ASCO ELECTED OFFICERS. THE AMENDMENTS ALSO EXPANDED THE NUMBER OF ASCO MEMBERS WHO HAD THESE RIGHTS ANY ONCOLOGY MEDICAL PROFESSIONAL WITH A DOCTORAL-LEVEL DEGREE MAY BE A VOTING MEMBER. THE CHANGES WERE PROJECTED TO PERMIT APPROXIMATELY 83% OF TOTAL ASCO MEMBERSHIP TO HAVE VOTING RIGHTS AND BE ELIGIBLE TO SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS AN ELECTED OFFICER. EXPANDED DIVERSITY ON THE BOARD OF DIRECTORS. PREVIOUSLY, THE BYLAWS REQUIRED THAT ALL MEMBERS OF THE BOARD OF DIRECTORS BE ONCOLOGISTS, WHO HAD TO BE PHYSICIANS. THE AMENDMENTS TO THE BYLAWS PERMIT THOSE BOARD MEMBERS WHO SIT IN "UNDESIGNATED" BOARD SEATS TO BE ANY ONCOLOGY PROFESSIONAL WITH A DOCTORAL- LEVEL DEGREE (NOT LIMITED TO PHYSICIANS). UNCONTESTED PRESIDENTIAL ELECTION. PREVIOUSLY, THE ASCO NOMINATING COMMITTEE SELECTED TWO NOMINEES EACH YEAR FOR PRESIDENT-ELECT THAT WERE THEN PRESENTED TO THE ASCO MEMBERSHIP FOR VOTE. UNDER THE APPROVED AMENDMENTS, EACH YEAR THE NOMINATING COMMITTEE WILL SELECT TWO CANDIDATES FOR THE ROLE OF PRESIDENT-ELECT, WHO ARE SUBMITTED TO THE ASCO BOARD OF DIRECTORS, WHICH THEN SELECTS THE BEST CANDIDATE FROM THE TWO CHOICES. THAT CANDIDATE IS PRESENTED TO THE ASCO MEMBERS FOR ELECTION THE ASCO VOTING MEMBERS MAY VOTE FOR THAT CANDIDATE, WRITE IN AN ALTERNATE CANDIDATE, OR ABSTAIN FROM VOTING. THIS CHANGE WAS INTENDED TO PERMIT THE NOMINATING COMMITTEE TO BETTER SUPPORT DIVERSITY IN THE ROLE OF PRESIDENT-ELECT FROM YEAR TO YEAR, WITH THE EXPECTATION THAT OVER THE LONG TERM, THE ASCO PRESIDENCY WILL REFLECT THE DIVERSITY OF THE MEMBERSHIP IN EVERY WAY: SPECIALTY, PROFESSIONAL SETTING, DEMOGRAPHICS, ANDOTHER CHARACTERISTICS. CONTINUITY IN THE ROLE OF TREASURER. PREVIOUSLY, THE ROLE OF TREASURER WAS TREATED AS A UNIQUE SEAT ON THE BOARD OF DIRECTORS, WITH ASCO MEMBERS VOTING FOR A CANDIDATE TO SERVE AS TREASURER EVERY FOUR YEARS. UNDER THE AMENDED BYLAWS, THE TREASURER-ELECT WILL BE ELECTED EACH YEAR FROM AMONG THE SERVING BOARD MEMBERS BY THE BOARD OF DIRECTORS. THE TREASURER-ELECT WILL SERVE A ONE-YEAR TERM, AND THEN SERVE A ONE-YEAR TERM AS TREASURER. THIS CHANGE WAS INTENDED TO ENSURE THAT THE ASCO TREASURER WOULD ALREADY HAVE EXPERIENCE WITH SOCIETY OPERATIONS FROM THEIR SERVICE ON THE BOARD AND AS TREASURER-ELECT BEFORE SERVING AS TREASURER. COMPOSITION OF NOMINATING COMMITTEE. PREVIOUSLY, THE NOMINATING COMMITTEE WAS COMPOSED OF THE ASCO PRESIDENT, CHAIR, AND THOSE OTHER NOMINATING COMMITTEE MEMBERS THAT WERE ELECTED BY THE ASCO MEMBERS. UNDER THE AMENDED BYLAWS, THE ASCO PRESIDENT-ELECT AND PAST PRESIDENT HAVE BEEN ADDED TO THE NOMINATING COMMITTEE. APPROVAL OF BYLAWS AMENDMENTS. PREVIOUSLY, PROPOSED AMENDMENTS HAD TO BE APPROVED BY A TWO-THIRDS VOTE OF THE ASCO MEMBERS ELIGIBLE TO VOTE TO BECOME EFFECTIVE. UNDER THE AMENDED BYLAWS, PROPOSED AMENDMENTS TO THE BYLAWS MUST BE APPROVED BY THE VOTE OF A MAJORITY OF THE VOTES CAST BY VOTING-ELIGIBLE MEMBERS TO BECOME EFFECTIVE. FORM 990, PART VI, SECTION A, LINE 6 VOTING MEMBERS. ALL ASCO MEMBERS MUST BE ONCOLOGY MEDICAL PROFESSIONALS, DEFINED AS INDIVIDUALS WHO MEET ANY OF THE FOLLOWING QUALIFICATIONS: (1) INDIVIDUALS WHOSE PROFESSIONAL CREDENTIALS AND ACTIVITIES INVOLVE CANCER PATIENT CARE AND/OR RESEARCH, EDUCATION, OR ADVOCACY IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER; (2) INDIVIDUALS WHO ARE RETIRED FROM PROFESSIONAL ACTIVITIES, BUT WHOSE PROFESSIONAL ACTIVITIES PRIOR TO RETIREMENT INCLUDED THOSE SET FORTH ABOVE; (3) INDIVIDUALS WHO ARE STUDENTS TRAINING TO BE PROFESSIONALS DESCRIBED ABOVE. VOTING MEMBERS ARE ONCOLOGY MEDICAL PROFESSIONALS WHO HAVE BEEN AWARDED AND HOLD THE DEGREE OF DOCTOR OF MEDICINE, DOCTOR OF OSTEOPATHY, DOCTOR OF PHILOSOPHY, DOCTOR OF PHARMACY, DOCTOR OF MEDICAL SCIENCE, DOCTOR OF NURSING SCIENCE, DOCTOR OF NURSING PRACTICE, OR EQUIVALENT DOCTORAL-LEVEL DEGREE AS DETERMINED FROM TIME TO TIME BY ASCO AND THE ASSOCIATION. ONLY VOTING MEMBERS ARE ELIGIBLE TO VOTE OR SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS ELECTED OFFICERS. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE EXECUTIVE VICE PRESIDENT & CHIEF FINANCIAL OFFICER; THE CHIEF EXECUTIVE OFFICER; AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX- EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2021. THE COMPENSATION OF THE FOLLOWING POSITIONS WAS CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR EACH OF THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER & ASCO SECRETARY (EVP & COO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & COO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. THE EVP & COO'S COMPENSATION WAS ALSO REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, AS REQUIRED UNDER STATE LAW. - EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (EVP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CFO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (EVP & CC CEO): THE EVP & CC CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (EVP & CLQ CEO): THE EVP & CLQ CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. FORM 990, PART VI, SECTION C, LINE 18 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 7,314,021. MANAGEMENT AND GENERAL EXPENSES 1,886,264. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 9,200,285. DATA CURATION: PROGRAM SERVICE EXPENSES 7,743,865. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,743,865. PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 750,795. MANAGEMENT AND GENERAL EXPENSES 228,122. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 978,917. TEMPORARY STAFF: PROGRAM SERVICE EXPENSES 601,862. MANAGEMENT AND GENERAL EXPENSES 124,702. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 726,564. FORM 990, PART XI, LINE 9: PRIOR PERIOD ADJUSTMENT 1,326,214. ASCO LEASING LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 0 0 ASCO CANCERLINQ LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMPV VA 27768483 13122422 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 GRANTMAKING VA 501(C)(3) LINE 7 ASCO 1 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561693 MEMBER SERVS VA 501(C)(6) ASCO 1 ASCO ASSOCIATION POLITICAL ACTION COMM 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 ADVOCACY VA 527 ASCO ASSOC 0 CANCERLINQ LABS LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 881804716 DATABASE TECHNOLOGY VA N/A C 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 ASCO ASSOCIATION A 270897 FMV CONQUER CANCER FOUNDATION OF ASCO B 3566050 FMV CONQUER CANCER FOUNDATION OF ASCO C 7751511 FMV ASCO ASSOCIATION C 75000 FMV ASCO ASSOCIATION D 4696784 FMV ASCO ASSOCIATION L 1318578 CONQUER CANCER FOUNDATION OF ASCO L 98104 CONQUER CANCER FOUNDATION OF ASCO Q 6800390 ASCO ASSOCIATION Q 2895608 ASCO ASSOCIATION P 306785